Reviewing BioTelemetry (BEAT) & Cannabis Science (CBIS)
BioTelemetry (NASDAQ: BEAT) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Insider & Institutional Ownership
82.2% of BioTelemetry shares are owned by institutional investors. 9.6% of BioTelemetry shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares BioTelemetry and Cannabis Science’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioTelemetry||$208.33 million||4.18||$53.43 million||$1.31||20.50|
BioTelemetry has higher revenue and earnings than Cannabis Science.
This table compares BioTelemetry and Cannabis Science’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
BioTelemetry has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -4.04, meaning that its stock price is 504% less volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for BioTelemetry and Cannabis Science, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioTelemetry currently has a consensus price target of $43.50, indicating a potential upside of 62.01%. Given BioTelemetry’s higher possible upside, equities research analysts clearly believe BioTelemetry is more favorable than Cannabis Science.
BioTelemetry beats Cannabis Science on 9 of the 9 factors compared between the two stocks.
BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).
About Cannabis Science
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.